<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Technical advances have led to stool DNA (sDNA) tests that might accurately detect <z:hpo ids='HP_0002664'>neoplasms</z:hpo> on both sides of the colorectum </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed colorectal <z:hpo ids='HP_0002664'>neoplasm</z:hpo> detection by a next-generation sDNA test and effects of covariates on test performance </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We performed a blinded, multicenter, case-control study using archived stool samples collected in preservative buffer from 252 patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), 133 with <z:mpath ids='MPATH_270'>adenomas</z:mpath> ≥ 1 cm, and 293 individuals with <z:mpath ids='MPATH_458'>normal</z:mpath> colonoscopy results (controls); two-thirds were randomly assigned to a training set and one-third to a test set </plain></SENT>
<SENT sid="3" pm="."><plain>The sDNA test detects 4 methylated genes, a mutant form of KRAS, and the α-actin gene (as a reference value) using quantitative, allele-specific, real-time target and signal amplification; it also quantifies <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>We used a logistical model to analyze data </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The sDNA test identified 85% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and 54% of patients with <z:mpath ids='MPATH_270'>adenomas</z:mpath> ≥1 cm with 90% specificity </plain></SENT>
<SENT sid="6" pm="."><plain>The test had a high rate of detection for <z:hpo ids='HP_0000001'>all</z:hpo> nonmetastatic stages of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (aggregate 87% detection rate for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> stages I-III) </plain></SENT>
<SENT sid="7" pm="."><plain>Detection rates increased with <z:mpath ids='MPATH_270'>adenoma</z:mpath> size: 54% ≥ 1 cm, 63% &gt;1 cm, 77% &gt;2 cm, 86% &gt;3 cm, and 92% &gt;4 cm (P &lt; .0001) </plain></SENT>
<SENT sid="8" pm="."><plain>Based on receiver operating characteristic analysis, the rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> detection was slightly greater for the training than the test set (P = .04), whereas the rate of <z:mpath ids='MPATH_270'>adenoma</z:mpath> detection was comparable between sets </plain></SENT>
<SENT sid="9" pm="."><plain>Sensitivities for detection of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:mpath ids='MPATH_270'>adenoma</z:mpath> did not differ with lesion site </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Early-stage <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and large <z:mpath ids='MPATH_270'>adenomas</z:mpath> can be detected throughout the colorectum and with high levels of accuracy by the sDNA test </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0002664'>Neoplasm</z:hpo> size, but not anatomical site, affected detection rates </plain></SENT>
<SENT sid="12" pm="."><plain>Further studies are needed to validate the findings in a larger population and optimize the sDNA test </plain></SENT>
</text></document>